Abstracts Archive - Page 1234 of 2425 - ACR Meeting Abstracts

Abstract Number: 427 • 2017 ACR/ARHP Annual Meeting
Do We Treat Men and Women Differently, and Is This a Good Thing?
Sytske Anne Bergstra¹, Cornelia F Allaart¹, Sofia Ramiro², Arvind Chopra³, Candida A. Silva⁴, Nimmisha Govind⁵ and Robert B.M. Landewé^6,7, ¹Department of Rheumatology, LUMC, Leiden, Netherlands, Leiden, Netherlands, ²Rheumatology, Department of Rheumatology, LUMC, Leiden, Netherlands, Leiden, Netherlands, ³Center for Rheumatic Diseases, Pune, India, Pune, India, ⁴Instituto Português de Reumatologia, Lisbon, Portugal, Lisbon, Portugal, ⁵Department of Rheumatology, University of the Witwatersrand, Johannesburg, South-Africa, Johannesburg, South Africa, ⁶Zuyderland Medical Center, Heerlen, Netherlands, Heerlen, Netherlands, ⁷Amsterdam Rheumatology & Immunology Center, Netherlands, Amsterdam, Netherlands
Background/Purpose: Men seem to respond better to antirheumatic treatment than women with RA. In daily practice, expectations towards responsiveness may influence rheumatologists when making treatment…
Abstract Number: 428 • 2017 ACR/ARHP Annual Meeting
Impact of Smoking Cessstion Advise in Patients with Rheumatoid Arthritis to Help Quit Smoking
Shama Khan¹, Ahmad Butt¹, Emmett Brennan², Ausaf Mohammad¹ and Killian O Rourke³, ¹Rheumatology, Midlands Regional Hospital, Tullamore, Ireland, ²Tullamore, Midlands Regional Hospital, Tullamore, Ireland, ³Rheumatology, Midlands Regional Hospital, Tullamore, Co Offaly, Ireland
Background/Purpose: Smoking is associated with an increased risk of comorbidities in rheumatoid arthritis (RA) and may reduce the efficacy of anti-rheumatic therapies. Smoking cessation is…
Abstract Number: 429 • 2017 ACR/ARHP Annual Meeting
Repair of Joint Damage Is Rare in Newly Diagnosed Rheumatoid Arthritis Patients and Appears Not to Relate to Previous Suppression of Inflammation
Joy A. van der Pol¹, Gulsah Akdemir¹, Marianne van den Broek¹, Linda Dirven¹, Pit J.S.M. Kerstens², Willem F. Lems³, Iris M. Markusse¹, Cornelia F Allaart¹ and Tom W.J. Huizinga¹, ¹Department of Rheumatology, LUMC, Leiden, Netherlands, Leiden, Netherlands, ²Department of Rheumatology, Reade, Amsterdam, Netherlands, ³Department of Rheumatology, VU Medical Center, Amsterdam, Netherlands, Amsterdam, Netherlands
Background/Purpose: Joint damage in RA is thought to be irreparable. We hypothesized that in patients in whom inflammation is persistently well suppressed, repair may be…
Abstract Number: 430 • 2017 ACR/ARHP Annual Meeting
Implementation of a Treat-to-Target Remission Strategy for Rheumatoid Arthritis in Australian Public and Private Rheumatology Clinics – Identification of Clinician and Patient Barriers
Helen Benham¹, Hedva Chiu², Joanne Tesiram³, Peter Landsberg⁴, Andrew A. Harrison⁵, Peter Nash⁶, Ranjeny Thomas⁷ and Mieke van Driel⁸, ¹The University of Queensland Faculty of Medicine, Brisbane, Australia, ²The University of Queensland Faculty of Medicine, Woolloongabba, Australia, ³Rheumatology, Princess Alexandra Hospital, Woolloongabba, Australia, ⁴Princess Alexandra Hospital, Woolloongabba, Australia, ⁵Department of Medicine, University of Otago Wellington, Wellington, New Zealand, ⁶University of Queensland, Brisbane, Australia, ⁷Diamantina Institute, Diamantina Institute University of Queensland, Brisbane, Australia, ⁸Primary Care Clinical Unit, The University of Queensland Faculty of Medicine, Herston, Australia
Background/Purpose: Treat-to-target in rheumatoid arthritis (RA-T2T) improves outcomes for people living with RA. Implementing T2T in routine clinical practice however presents many challenges and an…
Abstract Number: 431 • 2017 ACR/ARHP Annual Meeting
Post-Marketing Surveillance of Tofacitinib in Japanese Patients with Rheumatoid Arthritis: An Interim Report of Safety Data
Tsuneyo Mimori¹, Masayoshi Harigai², Tatsuya Atsumi³, Masataka Kuwana⁴, Syuji Takei⁵, Naoto Tamura⁶, Takao Fujii⁷, Hiroaki Matsuno⁸, Shigeki Momohara⁹, Kazuhiko Yamamoto¹⁰, Takeshi Kokubo¹¹, Yutaka Endo¹¹, Naonobu Sugiyama¹¹, Tomohiro Hirose¹¹, Yosuke Morishima¹¹ and Noritoshi Yoshii¹¹, ¹Kyoto University, Kyoto, Japan, ²Division of Epidemiology and Pharmacoepidemiology of Rheumatic Diseases, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ³Hokkaido University, Sapporo, Japan, ⁴Nippon Medical School, Tokyo, Japan, ⁵Kagoshima University, Kagoshima, Japan, ⁶Juntendo University, Tokyo, Japan, ⁷Wakayama Medical University, Wakayama, Japan, ⁸Matsuno Clinic for Rheumatic Diseases, Toyama, Japan, ⁹Hakkeikai Inc Medical Institution, Shizuoka, Japan, ¹⁰University of Tokyo, Tokyo, Japan, ¹¹Pfizer Japan Inc, Tokyo, Japan
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Efficacy and safety of tofacitinib have been shown in patients…
Abstract Number: 432 • 2017 ACR/ARHP Annual Meeting
ACPA and RF As Predictors of Sustained Clinical Remission in Rheumatoid Arthritis Patients: Data from a Rheumatoid Arthritis Cohort
Janet E. Pope¹, Emmanouil Rampakakis², Mohammad Movahedi³, Angela Cesta³, John S. Sampalis⁴ and Claire Bombardier³, ¹Department of Medicine, Division of Rheumatology, University of Western Ontario, St Joseph's Health Care, London, ON, Canada, ²JSS Medical Research, Montreal, QC, Canada, ³Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ⁴McGill University, Montreal, QC, Canada
ACPA and RF as Predictors of Sustained Clinical Remission in Rheumatoid Arthritis Patients: Data From a Rheumatoid Arthritis CohortBackground/Purpose: Positive serology for anti-citrullinated protein antibody…
Abstract Number: 433 • 2017 ACR/ARHP Annual Meeting
Predictors of Earlier Biologic Initiation Among Patients with Rheumatoid Arthritis Starting Methotrexate
Michael D. George¹, Brian Sauer², Chia-Chen Teng, MS², Grant Cannon², Bryant R. England³, Gail S. Kerr⁴, Ted R. Mikuls⁵ and Joshua Baker⁶, ¹Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ²Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ³Division of Rheumatology & Immunology, Department of Internal Medicine, Nebraska-Western IA VA Health Care System & University of Nebraska Medical Center, Omaha, NE, ⁴VAMC, Georgetown University, Washington, DC, ⁵Internal Medicine, Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ⁶Rheumatology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Biologic therapy for the treatment of RA has increased dramatically and has substantially increased costs of care. This study aimed to identify factors associated…
Abstract Number: 434 • 2017 ACR/ARHP Annual Meeting
Factors Associated with Treatment Adherence in Rheumatoid Arthritis: A Systematic Literature Review
Ee Teng Goh¹, Alvin Jian Xiong Soo¹, James Galloway², Sam Norton³ and Elena Nikiphorou⁴, ¹UCL Medical School, University College London, London, United Kingdom, ²King's College, and King´s College Hospital, London, United Kingdom, ³Academic Rheumatology, King´s College London, London, United Kingdom, ⁴Academic Rheumatology Department, King's College London, London, United Kingdom
Background/Purpose: Nonadherence to treatment in rheumatoid arthritis (RA) has been shown to negatively impact on treat to target goals and disease outcomes. Identifying and targeting…
Abstract Number: 435 • 2017 ACR/ARHP Annual Meeting
Characteristics of Rheumatoid Arthritis Patients Who Have a DMARD Interruption and the Impact of Using a Bridging Medication on Clinical and Patient Reported Outcomes
Christine Iannaccone¹, Michelle Frits², Taysir G. Mahmoud³, Gabriela Maica⁴, Jonathan Coblyn⁵, Michael Weinblatt² and Nancy A. Shadick⁶, ¹Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ²Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ³Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁴Department of Rheumatology, Allergy, and Immunology, Brigham and Women's Hospital, Boston, MA, ⁵Department of Rheumatology, Brigham & Womens Hospital, Boston, MA, ⁶Rheumatology Immunology & Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: It is common for RA patients to interrupt their DMARD use due to events like infection, surgery, or pregnancy. Many RA patients may need…
Abstract Number: 436 • 2017 ACR/ARHP Annual Meeting
Baseline Anemia As a Predictor of Radiographic Progression in Tofacitinib-Treated Rheumatoid Arthritis Patients: Post Hoc Analyses from Two Phase 3 Trials
Burkhard Moeller¹, Axel Finckh², Godehard Scholz¹, Harry Shi³, Carol A Connell⁴ and Sander Strengholt⁵, ¹Department for Rheumatology, Immunology and Allergology, University Hospital of Bern, Bern, Switzerland, ²University Hospital of Geneva, Geneva, Switzerland, ³Pfizer Inc, Collegeville, PA, ⁴Pfizer Inc, Groton, CT, ⁵Pfizer Inc, Capelle aan den IJssel, Netherlands
Background/Purpose: Anemia in patients with rheumatoid arthritis (RA) can help to identify those with more rapid erosive disease.1,2 Tofacitinib is an oral Janus kinase inhibitor…
Abstract Number: 437 • 2017 ACR/ARHP Annual Meeting
Recruitment of RA Trials in the Modern Era: Are United States-Based Trials Still Feasible?
Carla Maldini^1,2, Alfred Mahr³, David T. Felson^4,5 and Michael P. LaValley⁶, ¹Internal Medicine, Hospital Saint-Louis, Paris, France, ²Rheumatology, Hospital Córdoba, Cordoba, Argentina, ³Internal Medicine, University Hospital Saint-Louis, Paris, France, ⁴Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston, MA, ⁵Arthritis Research UK Centre for Epidemiology, Institute of Inflammation and Repair, University of Manchester, Manchester, United Kingdom, ⁶Biostatistics, Boston University School of Public Health, Boston, MA
Background/Purpose: Timely recruitment of patients into interventional trials is necessary for their successful completion. The aim of this study was to evaluate recruitment rates of…
Abstract Number: 438 • 2017 ACR/ARHP Annual Meeting
High Multi-Biomarker Disease Activity Score Is Associated with High Risk of Radiographic Progression in Six Cohorts
Jeffrey R. Curtis¹, Cecilie Heegaard Brahe², Mikkel Østergaard³, Merete Lund Hetland², Karen Hambardzumyan⁴, Saedis Saevarsdottir⁴, Xingbin Wang⁵, Eric H. Sasso⁵ and Tom W.J. Huizinga⁶, ¹Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²Copenhagen Center for Arthritis Research, Copenhagen, Denmark, ³Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Denmark, Copenhagen, Denmark, ⁴Karolinska Institute and Karonlinska University Hospital, Stockholm, Sweden, ⁵Crescendo Bioscience Inc., South San Francisco, CA, ⁶Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: The multi-biomarker disease activity (MBDA) test uses a validated algorithm with 12 serum protein biomarkers to assess disease activity in patients with RA. The…
Abstract Number: 439 • 2017 ACR/ARHP Annual Meeting
Analysis of Rheumatoid Arthritis Patients That Did Not Achieve the Treatment Goal By the Treat-to-Target Strategy in Daily Practice
Hideshi Yamazaki and Tetsuo Takanashi, Center for Rheumatic Disease, Marunouchi Hospital, Matsumoto, Japan
Background/Purpose: Although the goal of rheumatoid arthritis (RA) treatment is to achieve remission or low disease activity with the treat-to-target (T2T) strategy, some patients do…
Abstract Number: 440 • 2017 ACR/ARHP Annual Meeting
Rheumatoid Arthritis Patient´s Journey: Delay in Diagnosis and Treatment
Aurelia Luissi¹, Florencia Pierini¹, Maria Victoria Garcia¹, Mirtha Sabelli¹, Marina Scolnik¹, Santiago Ruta¹, Javier Rosa¹ and Enrique R Soriano², ¹Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, CABA, Argentina, ²Argentina, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
Background/Purpose: there is a wide variation in the time elapsed between first symptoms and diagnosis of RA, ranging from 1 month to 10 years in…
Abstract Number: 441 • 2017 ACR/ARHP Annual Meeting
Social Media Based, Direct-to-Patient Study Designed for Development of “from Home” Testing for Rheumatoid Arthritis Patients Is Feasible and Engaged Individuals with Distinct Clinical Characteristics
Kristen Warren¹, Olga Derbeneva¹, Francisco Flores¹, Michelle Frits², James Healy¹, Christine Iannaccone³, Omar Khalid¹, Krishna Morampudi¹, Nancy Shadick⁴, Michael Weinblatt⁴, Hemani Wijesuriya¹ and Robert Terbrueggen¹, ¹DxTerity, Rancho Dominguez, CA, ²Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ³Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁴Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Physicians equipped with low cost, patient-administered, “from home” genomic tests for monitoring disease activity and therapy response could revolutionize treatment for rheumatoid arthritis…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].